micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: the Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition

Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: the Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition

Source : https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc23-2336/154414/Associations-of-Dietary-Cholesterol-Consumption?redirectedFrom=fulltext

OBJECTIVE. Whether genetic susceptibility to disease and dietary cholesterol (DC) absorption contribute to inconsistent associations of DC consumption with

Dietary cholesterol consumption was not associated with incident diabetes and CVD in the overall sample and in subgroups stratified by genetic predisposition to cholesterol absorption and the diseases.

Profile Image
  • Saved

2yr
Failure of Lipid Control by PCSK9 Inhibitors in Compound Heterozygous Familial Hypercholesterolemia Complicated With Premature Myocardial Infarction: a Case Report

Failure of Lipid Control by PCSK9 Inhibitors in Compound Heterozygous Familial Hypercholesterolemia Complicated With Premature Myocardial Infarction: a Case Report

Source : https://pubmed.ncbi.nlm.nih.gov/38487640/

Familial hypercholesterolemia (FH) is a serious autosomal dominant disorder. Managing blood lipids in FH patients poses greater challenges for clinicians. Drug therapy may not always yield satisfactory results, particularly in...

The inefficacy of proprotein-converting enzymes/kexin 9 inhibitors may arise from the extensive mutations, leading to loss of low-density lipoprotein receptor activity.

Profile Image
  • Saved

2yr
PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38310920/

Novo Nordisk.

The estimated treatment difference between NNC0385-0434 100 mg and evolocumab 140 mg was 3.4%.

Profile Image
  • Saved

2yr
An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

Source : https://pubmed.ncbi.nlm.nih.gov/38593947/

An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns.

The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 versus usual care.

Profile Image
  • Saved

2yr
A Wrap Up of The American College of Cardiology 2024 Scientific Session

This year’s meeting marked the 75th anniversary of ACC and included practice-changing information on the prevention, diagnosis, and treatment of the full spectrum of cardiovascular diseases. Click to access our postconference wrap-up report.